Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3350631
Max Phase: Preclinical
Molecular Formula: C22H31N10O18P3
Molecular Weight: 816.46
Molecule Type: Small molecule
Associated Items:
ID: ALA3350631
Max Phase: Preclinical
Molecular Formula: C22H31N10O18P3
Molecular Weight: 816.46
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CO[C@H]1[C@@H](O)[C@H](n2c[n+](C)c3c(O)nc(N)nc32)O[C@@H]1COP(=O)(O)OP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O
Standard InChI: InChI=1S/C22H31N10O18P3/c1-30-6-32(16-10(30)18(37)29-22(24)27-16)20-13(35)14(44-2)8(48-20)4-46-52(40,41)50-53(42,43)49-51(38,39)45-3-7-11(33)12(34)19(47-7)31-5-25-9-15(31)26-21(23)28-17(9)36/h5-8,11-14,19-20,33-35H,3-4H2,1-2H3,(H8-,23,24,26,27,28,29,36,37,38,39,40,41,42,43)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
Standard InChI Key: AIRSQUYUYJSIIM-XPWFQUROSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 816.46 | Molecular Weight (Monoisotopic): 816.1031 | AlogP: -4.11 | #Rotatable Bonds: 13 |
Polar Surface Area: 410.46 | Molecular Species: ACID | HBA: 24 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 28 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.86 | CX Basic pKa: 1.88 | CX LogP: -9.01 | CX LogD: -13.68 |
Aromatic Rings: 4 | Heavy Atoms: 53 | QED Weighted: 0.05 | Np Likeness Score: 0.85 |
1. Rydzik AM, Kulis M, Lukaszewicz M, Kowalska J, Zuberek J, Darzynkiewicz ZM, Darzynkiewicz E, Jemielity J.. (2012) Synthesis and properties of mRNA cap analogs containing imidodiphosphate moiety--fairly mimicking natural cap structure, yet resistant to enzymatic hydrolysis., 20 (5): [PMID:22316555] [10.1016/j.bmc.2012.01.013] |
2. Warminski M, Kowalska J, Buck J, Zuberek J, Lukaszewicz M, Nicola C, Kuhn AN, Sahin U, Darzynkiewicz E, Jemielity J.. (2013) The synthesis of isopropylidene mRNA cap analogs modified with phosphorothioate moiety and their evaluation as promoters of mRNA translation., 23 (13): [PMID:23726029] [10.1016/j.bmcl.2013.05.001] |
3. Ziemniak M, Kowalska J, Lukaszewicz M, Zuberek J, Wnek K, Darzynkiewicz E, Jemielity J.. (2015) Phosphate-modified analogues of m(7)GTP and m(7)Gppppm(7)G-Synthesis and biochemical properties., 23 (17): [PMID:26264844] [10.1016/j.bmc.2015.07.052] |
Source(1):